tbuckley/cabot-search huggingface dataset:
Oncology nurse perspectives on the nature and meaning of their positive relationships with seriously ill patients.
Authors: Emily M. Wright, Alaina Carr, Barbara J. Cashavelly, William F. Pirl, Lara Traeger
Journal: Journal of Clinical Oncology (2017)

42 Background: Inpatient oncology nurses regularly care for patients at or near the end of life. Given increasing attention to risk of compassion fatigue in this setting, we conducted a qualitative study to explore nurses’ perspectives on the nature and meaning of their positive relationships with patients who were seriously ill or dying. Methods: We conducted in-depth interviews with 24 registered nurses (RN)s working on an inpatient medical oncology unit at an academic medical center. We used a semi-structured interview guide to elicit RNs’ descriptions of ‘good’ relationships they had with patients/families with attention to aspects that made these relationships meaningful. Using a framework approach, including an iterative coding process, two team members independently coded all interview data (Kappa = .80) and worked with a multidisciplinary team to identify themes. Results: RNs (95.8% female; 95.8% non-Hispanic white, M age = 32.7 yrs [SD = 10.8 yrs], median yrs as RN = 4.0 [range: 1.5-35.0 yrs]) described specific cases in which they felt they had developed ‘good’ relationships with patients and families. RN descriptions centered on highly intimate and transformative moments in patient/family care. These unique moments occurred in the context of longitudinal nurse-patient relationships in which RNs felt able to 1) facilitate patient/family processing of emotions and disclosure of treatment preferences that they otherwise were not able to process or disclose to other loved ones or clinicians; 2) provide highly-skilled patient-centered care to reduce patient suffering; and/or 3) facilitate patient/family prognostic understanding and peace at the end of life. RNs felt privileged to serve these roles. Memorable transformative moments enriched RNs’ professional identities and inspired their continued work. Conclusions: Inpatient oncology nurse-patient relationships serve distinctive functions for both patient-centered care and RN well being. Results underscore the importance of assisting RNs in managing patient symptoms, forming longitudinal relationships with patients/families, and coping with factors that impede ‘good’ relationships.
Long-term efficacy and safety of duloxetine in the management of painful chemotherapy induced peripheral neuropathy.
Authors: Sang Mi Ro, In Sook Woo
Journal: Journal of Clinical Oncology (2017)

236 Background: Accordingly, Quality of life in the survivorship of patients with cancer is becoming one of the important issues with a development of systemic anticancer treatment. About 40% of the patients who receive chemotherapeutic agents which have neuropathic potential suffer from painful CIPN. Various approaches to relieve the pain associated with CIPN have been attempted in clinical practice. Previously duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine, has been reported to reduce painful CIPN when administered for 5 weeks. We retrospectively investigated the effect of duloxetine on the pain associated with CIPN over a prolonged period of administration. Methods: Between December 2014 and December 2016, patients with advanced cancer who complained of CIPN during or after systemic chemotherapy were eligible. Initially, 30 mg of duloxetine was administered daily for the first week and 60 mg daily was administered from the second week thereafter. The severity of pain was evaluated using a numerical rating scale from 0 to 10. Study follow-up was performed at regular visits according to the chemotherapy schedule or at the time of evaluation of disease status in the patients who completed systemic chemotherapy. However, the patients were allowed to visit whenever needed. Results: Twenty-seven patients were evaluable, the median age was 64 years (range, 23-83 years), and 11 patients were male and 16 patients were female. Twenty-four of the 27 patients received neurotoxic chemotherapeutic agents such as cisplatin, oxaliplatin, taxane and vinca alkaloid. Patients receiving duloxetine showed a significant reduction in the pain intensity from baseline and the mean decrease in the average pain score was 2.85 (95% CI 2.26-3.44, P &lt; 0.001). Twenty-five (92.5%) of the 27 patients showed decreased pain after the use of duloxetine. Mean duration of treatment was 29 weeks (range, 1~130 weeks). Median duration of response was 19 weeks (range, 4~99 weeks). Treatment-related adverse events were nausea (17.2%), vomiting (3.4%) and dizziness (6.8%). Conclusions: Duloxetine demonstrated a durable efficacy and tolerability for painful CIPN in patients with advanced cancer.
P2.03-055 Comparison of Afatinib Versus Erlotinib for Advanced Non-Small-Cell Lung Cancer Patients with Resistance to EGFR-TKI
Authors: Y. Sakamori, Y. Yasuda, T. Funazo, T. Nomizo, T. Tsuji, H. Yoshida, H. Nagai, H. Ozasa, T. Hirai, Y.H. Kim
Journal: Journal of Thoracic Oncology (2017)
The enjoyment of negative emotions in the experience of magic
Authors: Jason Leddington
Journal: Behavioral and Brain Sciences (2017)

Theatrical magic is designed to elicit negative emotions such as feelings of vulnerability, loss of control, apprehension, fear, confusion, and bafflement. This commentary suggests that the Distancing-Embracing model can help us understand how the experience of magic can be aesthetically pleasurable, not despite, rather thanks to, some of the strong negative emotions it provokes.
Abstract 17343: Eicosapentaenoic Acid and the Eicosapentaenoic Acid/Arachidonic Acid Ratio is Associated With Prevalent Diabetes
Authors: John R Nelson, Michael R Mehan, Leigh E Alexander, Rosalynn D Gill
Journal: Circulation (2017)

Introduction:  Diabetes Mellitus (DM) is characterized by a dyslipidemic profile: low levels of high density lipoprotein cholesterol (HDL-C), high triglycerides (Tg), and high Tg/HDL-c ratio, which are associated with adverse cardiovascular (CV) outcomes. Low levels of eicosapentaenoic acid (EPA) and EPA/AA (arachidonic acid) ratio are associated with adverse CV outcomes. It is unknown if prevalence of DM is related to levels of EPA and EPA/AA ratio in a general population and whether it differs by gender as demonstrated in Tg/HDL-c ratio.   Methods:  A retrospective cohort of 55,765 samples (ages 18 - 80) was created from patients who received testing at Boston Heart Diagnostics. Test results were stratified by gender and split into quartiles. Odds ratios were calculated between each quartile and the first reference quartile. Area under the curve (AUC) were calculated from logistic regression models controlled for age.   Results:  DM prevalence decreased with increasing EPA (M: p trend    Conclusions:  This study shows for the first time that EPA and EPA/AA ratio are directly associated with prevalent DM. The association between these biomarkers and DM is stronger in females than in men. The AUC for EPA and the EPA/AA ratio is less than the Tg/HDL-C ratio, however, these biomarkers may be independent markers of DM risk.
Overall Survival vs Disease-Specific Survival
Authors: Harry B. Burke
Journal: JAMA Oncology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Abstract 20927: Use of a Novel Pre-Shaped Nitinol Esophageal Deviator (EsoSure®) to Successfully Ablate the Left Atrium Without Esophageal Temperature Rise During Atrial Fibrillation Ablation: The DEFLECT GUT Study
Authors: Dhanunjaya Lakkireddy, Valay Parikh, Madhu Reddy, Vijay Swarup, Jacob Hantla, Luigi Di Biase, Amin Al-Ahmed, Andrea Natale
Journal: Circulation (2017)

Background: Esophageal injury is a feared complication of atrial fibrillation (AF) ablation. Esophageal temperature monitoring has been used as a surrogate marker for potential esophageal thermal injury. Often times, rise in esophageal temperature during radiofrequency ablation (RFA) for AF limits the ability to deliver RF energy. Objective: The aim of this study was to evaluate the safety and efficacy of the EsoSure® (Northeast Scientific, Inc., Waterbury, CT), a mechanical esophageal deviation tool, during RFA for AF. Methods: In this prospective observational series, we evaluated 135 consecutive patients from 4 centers in whom luminal esophageal temperature (LET) rise or likely rise was limiting RFA lesion delivery on the posterior wall of the LA. EsoSure® was used to deflect the esophagus away from the ablation site in the LA. Light Barium was used to visualize and confirm esophageal displacement in all patients. Baseline demographics, procedural variables and complication rates were collected and evaluated. Patients were followed up to 3 months for clinical signs and symptoms of esophageal injury. Results: The mean age of our sample was 64 ± 10 years and 77 (57%) patients were males. Mean CHA2DS2-VASc score was 2.72 ± 1 and 97 (74 %) patients had paroxysmal AF. The mean deviation of the trailing edge of the esophagus with EsoSure® was 2.6 ± 1 cm (range: 0.8 - 4.5 cm). Successful intra-procedural end point, defined as successful pulmonary vein isolation, was achieved in 100% of patients. Among the 96 (71%) patients in whom EsoSure® was used after an increase in LET, the mean peak rise of LET was 1.3 ± 0.2° C prior to the EsoSure® use and 0.2 ± 0.1° C after the EsoSure® use (p&lt;0.001). There were no complications related to the EsoSure® use through 3-month follow-up. No symptoms suggestive of esophageal injury were noted related to AF ablation. Conclusions: Mechanical displacement of the esophagus with EsoSure® device appears to be safe and efficacious in enabling adequate RF energy delivery to the posterior wall of the LA during RFA for AF without significant luminal temperature rise and obvious clinical signs or symptoms of esophageal injury up to 3 months of follow up.
P2.03b-044 Treatment Outcome and the Role of Primary Tumor Therapy in a Cohort of Patients with Synchronous Oligometastatic NSCLC
Authors: Jose Carlos Ruffinelli, Arturo Navarro-Martin, Marta Doménech, Ramon Palmero, Susana Padrones, Ma Dolores Arnaiz, Samantha Aso, Ricard Ramos, Ivan Macia, Maria Plana, Carles Mesia, Francisco Rivas, Eduard Andia, Ariadna Conejero, Jose Luis Vercher, Isabel Brao, Monica Arellano, Felipe Cardenal, Ernest Nadal
Journal: Journal of Thoracic Oncology (2017)
CCR2 expression on circulating monocytes is associated with arterial wall inflammation assessed by 18F-FDG PET/CT in patients at risk for cardiovascular disease
Authors: Simone L Verweij, Raphaël Duivenvoorden, Lotte C A Stiekema, Nick S Nurmohamed, Fleur M van der Valk, Miranda Versloot, Hein J Verberne, Erik S G Stroes, Matthias Nahrendorf, Siroon Bekkering, Sophie J Bernelot Moens
Journal: Cardiovascular Research (2017)

Circulating monocytes infiltrate the plaque and differentiate into macrophages, contributing to an inflammatory environment which is associated with higher risk of cardiovascular events. Although the pivotal role of circulating monocytes in plaque inflammation has been firmly established, the search continues to identify specific monocyte subsets that may be especially atherogenic. Therefore, we evaluated the relation between monocyte phenotype, particularly surface receptor expression, and arterial wall inflammation in patients at increased cardiovascular risk. We performed a multivariate linear regression analysis in 79 patients at increased cardiovascular risk who had both an 18F-fluorodeoxyglucose positron emission tomography/computed tomography to assess arterial wall inflammation and extensive monocyte characterization (using flow cytometry). We found that CCR2, a monocyte chemokine receptor essential for transmigration, significantly correlates with arterial wall inflammation. This relationship was independent of traditional cardiovascular risk factors and statin use (β = 0.429, P = 0.015). We found no relation between arterial wall inflammation and monocyte count or monocyte subsets, namely CD14+CD16−, CD14+CD16+, CD14+CD16 ++, CCR5+, CD18+, CD11b+, or CD11c+ monocytes. Monocyte CCR2 expression is associated with arterial wall inflammation in patients at increased cardiovascular risk. Our data warrant further studies to assess if inhibition of CCR2 may attenuate atherosclerotic plaque inflammation.
Cohort-specific imputation of gene expression improves prediction of warfarin dose for African Americans
Authors: Assaf Gottlieb, Roxana Daneshjou, Marianne DeGorter, Stephane Bourgeois, Peter J. Svensson, Mia Wadelius, Panos Deloukas, Stephen B. Montgomery, Russ B. Altman
Journal: Genome Medicine (2017)

Genome-wide association studies are useful for discovering genotype–phenotype associations but are limited because they require large cohorts to identify a signal, which can be population-specific. Mapping genetic variation to genes improves power and allows the effects of both protein-coding variation as well as variation in expression to be combined into "gene level" effects. Previous work has shown that warfarin dose can be predicted using information from genetic variation that affects protein-coding regions. Here, we introduce a method that improves dose prediction by integrating tissue-specific gene expression. In particular, we use drug pathways and expression quantitative trait loci knowledge to impute gene expression—on the assumption that differential expression of key pathway genes may impact dose requirement. We focus on 116 genes from the pharmacokinetic and pharmacodynamic pathways of warfarin within training and validation sets comprising both European and African-descent individuals. We build gene-tissue signatures associated with warfarin dose in a cohort-specific manner and identify a signature of 11 gene-tissue pairs that significantly augments the International Warfarin Pharmacogenetics Consortium dosage-prediction algorithm in both populations. Our results demonstrate that imputed expression can improve dose prediction and bridge population-specific compositions. MATLAB code is available at https://github.com/assafgo/warfarin-cohort
Landscape of DNA Methylation on the Marsupial X
Authors: Shafagh A Waters, Alexandra M Livernois, Hardip Patel, Denis O’Meally, Jeff M Craig, Jennifer A Marshall Graves, Catherine M Suter, Paul D Waters
Journal: Molecular Biology and Evolution (2017)

DNA methylation plays a key role in maintaining transcriptional silence on the inactive X chromosome of eutherian mammals. Beyond eutherians, there are limited genome wide data on DNA methylation from other vertebrates. Previous studies of X borne genes in various marsupial models revealed no differential DNA methylation of promoters between the sexes, leading to the conclusion that CpG methylation plays no role in marsupial X-inactivation. Using reduced representation bisulfite sequencing, we generated male and female CpG methylation profiles in four representative vertebrates (mouse, gray short-tailed opossum, platypus, and chicken). A variety of DNA methylation patterns were observed. Platypus and chicken displayed no large-scale differential DNA methylation between the sexes on the autosomes or the sex chromosomes. As expected, a metagene analysis revealed hypermethylation at transcription start sites (TSS) of genes subject to X-inactivation in female mice. This contrasted with the opossum, in which metagene analysis did not detect differential DNA methylation between the sexes at TSSs of genes subject to X-inactivation. However, regions flanking TSSs of these genes were hypomethylated. Our data are the first to demonstrate that, for genes subject to X-inactivation in both eutherian and marsupial mammals, there is a consistent difference between DNA methylation levels at TSSs and immediate flanking regions, which we propose has a silencing effect in both groups.
Abstract 15963: Understanding Hospital Readmissions in Female Patients Admitted With Heart Failure Complicated by Atrial Fibrillation: A Get With the Guidelines - Heart Failure (GWTG-HF) Study
Authors: Mitra Daneshvar, Nayan Desai, Matthew Ortman, John Andriulli, Krystal Hunter, Eben Eno, Andrea Russo
Journal: Circulation (2015)

Background: Over 2.5 million women in the US have heart failure (HF) accounting for the leading cause of hospitalization in women over 65. Despite the high prevalence, women with HF are understudied and little remains known about how concurrent atrial fibrillation (AF) complicates the condition. Understanding key risk factors for readmission in female HF patients with AF may help to reduce the morbidity and mortality associated with this condition and help reduce the significant financial and resource burden these events have on the US healthcare system. Methods: The GWTG-HF study enrolled 615 female HF patients with AF between 2005 – 2012 at our center. Pearson χ 2 tests and the Student t-tests were used to compare patient characteristics and index hospital admission by future all-cause readmission status. Results: 92% of female patients with HF complicated by AF had a history of HF prior to index admission. 35% of these patients had a hospital readmission during the study period. Those who were readmitted were more likely to be black (p&lt;0.001). There was no difference in past medical history between groups. Isosorbide was slightly more likely to be prescribed in patients who had a subsequent readmission (p=0.043), without differences in other medications. Conclusion: Over one-third of female patients with HF complicated by AF had an all-cause readmission. Readmitted patients were more likely to be black with similar past medical history and mediations prescribed on discharge. Further study is needed to identify why black women are more likely to be readmitted, with investigation into the possible role of high medication costs, complex medical regimens, and other barriers to accessing the healthcare system. By understanding possible barriers that increase the risk of hospital readmission, efforts can be made to reduce these obstacles and improve the overall health of this group.
Abstract 17298: Comparative Effectiveness of Sulfonylurea versus Metformin in Patients With Heart Failure and Diabetes Mellitus
Authors: Abhinav Sharma, Adrian F Hernandez, Joseph Lucas, G. Michael Felker, Adam D DeVore
Journal: Circulation (2017)

Introduction: The optimal therapies for patients with diabetes mellitus (DM) and heart failure (HF) are unclear. We evaluated the comparative effectiveness of sulfonylurea versus biguanide (metform...
Abstract P4-15-01: Cost-effectiveness of pre-implantation genetic diagnosis for BRCA mutation carriers
Authors: JH Lipton, WWL Wong, E Warner, EM Greenblatt, EK Lee, KKW Chan
Journal: Cancer Research (2017)

Abstract Introduction: Management of BRCA mutation carriers is very expensive due to preventive surgeries and/or screening tests, as well as greater likelihood of cancer treatment. The related cancer burden and costs continue from generation to generation. One relatively new option for male or female BRCA mutation carriers, who wish to have children, is pre-implantation genetic diagnosis (PGD) of in vitro fertilized embryos. PGD eliminates the mutation from the descendants of these carriers. The purpose of this study was to model the cost-effectiveness of PGD. Methods: We developed a Markov Model using TreeAge Pro 2016 and compared incidence of cancers, cancers-related death, costs, quality adjusted life-years (QALY), and incremental cost-effectiveness ratio (ICER) in the 2nd generation associated with conventional management of BRCA mutation carriers vs. PGD using a U.S. third-party payer's perspective with a lifetime horizon at a discount rate of 3% per year. In the model, health states were implemented to reflect the natural history of breast and ovarian cancer for women, and prostate cancer (and breast cancer in BRCA2 mutation carriers) for men. Model data were obtained from published literature. Costs were determined from published data and insurance payment schedules. Results: Our preliminary results show that for BRCA1 mutation carriers, the PGD with IVF strategy is associated with an increase of 0.29 QALYs and costs an additional $292.68 per person, translating to an ICER of $1,014.25/QALY when compared with “No PGD”, making it highly cost-effective. For BRCA2 mutation carriers, the PGD with IVF strategy is associated with an increase of 0.17 QALYs and costs an additional $4,916.88 per person, translating to an ICER of $28,436.10/QALY when compared with “No PGD”, making it cost-effective. Table 1StrategyCost ($)Incr Cost ($)Eff (QALY)Incr Eff (QALY)Incr C/E ($/QALY) BRCA 1 No PGD323,347.22 28.41 PGD323,639.89292.6828.70.291,014.25BRCA 2 No PGD318,723.02 28.52 PGD323,639.894,916.8828.70.1728,436.10 Conclusion: PGD for both BRCA1 and BRCA2 mutation carriers reduces cancer burden, increases QALYs and, is very cost-effective in the 2nd generation cohort, making this an attractive option from the perspectives of patients and public payers. Our estimates are conservative because the cost-effectiveness of PGD will likely improve further if subsequent generations are included in the model, given the expected further reduction in cancer burden and associated cost-savings in subsequent generations. Citation Format: Lipton JH, Wong WWL, Warner E, Greenblatt EM, Lee EK, Chan KKW. Cost-effectiveness of pre-implantation genetic diagnosis for BRCA mutation carriers [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P4-15-01.
Abstract 15136: Incremental B-Type Natriuretic Peptide Reductions During Heart Failure Hospitalizations: Association With Lower 30-Day Readmission and 30-Day Mortality Among Patients With Serial Assays
Authors: Jose G Benuzillo, Kismet D Rasmusson, Abdallah G Kfoury, Colleen A Roberts, Donald L Lappé
Journal: Circulation (2017)

Introduction: Using B-type natriuretic peptide (BNP) during a heart failure (HF) hospitalization to ascertain diagnosis and prognosis has strong evidence, yet its use with serial measurement has no...
A social dimension to enjoyment of negative emotion in art reception
Authors: Brock Bastian
Journal: Behavioral and Brain Sciences (2017)

Abstract The proposed model overlooks the contribution of a relational/prosocial dimension to the enjoyment of negative emotion in art reception. Negative experiences have a unique capacity to build social bonds and may also increase motivation to “connect” with the artist. This affiliative motivation ensures that people experience an artwork as more emotional, more intense, more interesting, and ultimately more rewarding.
Phase 2 study of pembrolizumab for metastatic triple-negative breast cancer (mTNBC): Japanese subgroup results of KEYNOTE 086
Authors: M. Hattori, K. Tamura, H. Mukai, Y. Miyoshi, N. Masuda, E. Suzuki, H. Ishiguro, S. Ohtani, F. Hara, T. Shimamoto, K. Yamamoto, Y. Ding, G. Aktan, V. Karantza, H. Iwata
Journal: Annals of Oncology (2017)